{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:26:02Z","timestamp":1761863162296},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T00:00:00Z","timestamp":1354147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s11936-012-0219-0","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T07:18:25Z","timestamp":1354173505000},"page":"61-78","source":"Crossref","is-referenced-by-count":2,"title":["An Update on Drug-Eluting Stents"],"prefix":"10.1007","volume":"15","author":[{"given":"Scot","family":"Garg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,29]]},"reference":[{"issue":"23","key":"219_CR1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","volume":"346","author":"MC Morice","year":"2002","unstructured":"Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773\u201380.","journal-title":"N Engl J Med."},{"issue":"3","key":"219_CR2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-148-3-200802050-00199","volume":"148","author":"A Jeremias","year":"2008","unstructured":"Jeremias A, Kirtane A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann Intern Med. 2008;148(3):234\u20138.","journal-title":"Ann Intern Med."},{"issue":"11","key":"219_CR3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/CIRCULATIONAHA.106.666800","volume":"115","author":"E Camenzind","year":"2007","unstructured":"Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115(11):1440\u201355; discussion 55.","journal-title":"Circulation"},{"issue":"10","key":"219_CR4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa067722","volume":"356","author":"B Lagerqvist","year":"2007","unstructured":"Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10):1009\u201319.","journal-title":"N Engl J Med."},{"issue":"10","key":"219_CR5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMp068304","volume":"356","author":"A Farb","year":"2007","unstructured":"Farb A, Boam AB. Stent thrombosis redux\u2014the FDA perspective. N Engl J Med. 2007;356(10):984\u20137.","journal-title":"N Engl J Med."},{"issue":"2","key":"219_CR6","first-page":"152","volume":"30","author":"J Daemen","year":"2009","unstructured":"Daemen J, Simoons ML, Wijns W, et al. ESC forum on drug eluting stents european heart house, Nice, 27\u201328 September 2007. Eur Heart J. 2009;30(2):152\u201361.","journal-title":"Eur Heart J."},{"key":"219_CR7","unstructured":"Bazell R. Millions face risk from drug-coated stents. Published online 3\/1\/2007 on NBC News. Website: http:\/\/www.msnbc.msn.com\/id\/15816251\/ns\/health-heart_health\/t\/millions-face-risk-drug-coated-stents\/ - .UCF4tU1mRNI. 2007."},{"issue":"3","key":"219_CR8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/erc.09.138","volume":"8","author":"S Garg","year":"2010","unstructured":"Garg S, Serruys PW. Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Rev Cardiovasc Ther. 2010;8(3):449\u201370.","journal-title":"Expert Rev Cardiovasc Ther."},{"issue":"23","key":"219_CR9","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/eurheartj\/ehl282","volume":"27","author":"AJ Nordmann","year":"2006","unstructured":"Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27(23):2784\u2013814.","journal-title":"Eur Heart J."},{"issue":"12","key":"219_CR10","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2006.10.026","volume":"48","author":"M Pfisterer","year":"2006","unstructured":"Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48(12):2584\u201391.","journal-title":"J Am Coll Cardiol."},{"issue":"9591","key":"219_CR11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","volume":"370","author":"C Stettler","year":"2007","unstructured":"Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937\u201348.","journal-title":"Lancet."},{"issue":"22","key":"219_CR12","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/eurheartj\/ehm402","volume":"28","author":"A Kastrati","year":"2007","unstructured":"Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28(22):2706\u201313.","journal-title":"Eur Heart J."},{"key":"219_CR13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4244\/EIJV3I3A70","volume":"3","author":"J Daemen","year":"2007","unstructured":"Daemen J, Spaulding C, Jacob S, et al. A pooled safety analysis of data comparing paclitaxel-eluting stents with bare-metal stents. Eurointerv. 2007;3:392\u20139.","journal-title":"Eurointerv."},{"issue":"10","key":"219_CR14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa066633","volume":"356","author":"C Spaulding","year":"2007","unstructured":"Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356(10):989\u201397.","journal-title":"N Engl J Med."},{"issue":"10","key":"219_CR15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","volume":"356","author":"L Mauri","year":"2007","unstructured":"Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356(10):1020\u20139.","journal-title":"N Engl J Med."},{"issue":"10","key":"219_CR16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa067193","volume":"356","author":"GW Stone","year":"2007","unstructured":"Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356(10):998\u20131008.","journal-title":"N Engl J Med."},{"issue":"25","key":"219_CR17","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/CIRCULATIONAHA.108.826479","volume":"119","author":"AJ Kirtane","year":"2009","unstructured":"Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119(25):3198\u2013206.","journal-title":"Circulation."},{"issue":"18","key":"219_CR18","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jacc.2009.03.005","volume":"53","author":"PS Douglas","year":"2009","unstructured":"Douglas PS, Brennan JM, Anstrom KJ, et al. Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol. 2009;53(18):1629\u201341.","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"219_CR19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.amjcard.2008.03.055","volume":"102","author":"TL Pinto Slottow","year":"2008","unstructured":"Pinto Slottow TL, Steinberg DH, Roy PK, et al. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol. 2008;102(3):298\u2013303.","journal-title":"Am J Cardiol."},{"issue":"4","key":"219_CR20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4244\/EIJV5I4A79","volume":"5","author":"SK James","year":"2009","unstructured":"James SK, Wallentin L, Lagerqvist B. The SCAAR-scare in perspective. EuroIntervention. 2009;5(4):501\u20134.","journal-title":"EuroIntervention."},{"issue":"14","key":"219_CR21","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jacc.2008.07.006","volume":"52","author":"P Wenaweser","year":"2008","unstructured":"Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52(14):1134\u201340.","journal-title":"J Am Coll Cardiol."},{"issue":"17","key":"219_CR22","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jacc.2010.07.016","volume":"56","author":"DR Holmes Jr","year":"2010","unstructured":"Holmes Jr DR, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol. 2010;56(17):1357\u201365.","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"219_CR23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","volume":"48","author":"M Joner","year":"2006","unstructured":"Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193\u2013202.","journal-title":"J Am Coll Cardiol."},{"key":"219_CR24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacc.2010.06.007","volume":"56","author":"S Garg","year":"2010","unstructured":"Garg S, Serruys PW. Coronary stents-current status. J Am Coll Cardiol. 2010;56:S1\u2013S42. An in-depth review paper that summarises all data from randomised studies of 1st and 2nd generation DES.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"219_CR25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/CIRCULATIONAHA.111.031070","volume":"124","author":"GW Stone","year":"2011","unstructured":"Stone GW, Kedhi E, Kereiakes DJ, et al. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011;124(8):893\u2013900. A meta-analysis of everolimus versus paclitaxel stents that demonstrates an important interaction according to diabetic status.","journal-title":"Circulation."},{"key":"219_CR26","doi-asserted-by":"crossref","first-page":"126369","DOI":"10.1155\/2012\/126369","volume":"2012","author":"A Alazzoni","year":"2012","unstructured":"Alazzoni A, Al-Saleh A, Jolly SS. Everolimus-eluting versus paclitaxel-eluting stents in percutaneous coronary intervention: meta-analysis of randomized trials. Thrombosis. 2012;2012:126369.","journal-title":"Thrombosis."},{"issue":"4","key":"219_CR27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1161\/CIRCINTERVENTIONS.111.963256","volume":"4","author":"A Waha de","year":"2011","unstructured":"de Waha A, Dibra A, Byrne RA, et al. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2011;4(4):371\u20137. A meta-analysis of everolimus versus sirolimus stents that demonstrates comparable effiacacy between both stents.","journal-title":"Circ Cardiovasc Interv."},{"key":"219_CR28","doi-asserted-by":"crossref","unstructured":"Fan J, Du H, Yin Y et al. Efficacy and safety of zotarolimus-eluting stents compared with sirolimus-eluting stents in patients undergoing percutaneous coronary interventions - A meta-analysis of randomized controlled trials. Int J Cardiol. 2012.","DOI":"10.1016\/j.ijcard.2012.05.105"},{"issue":"9824","key":"219_CR29","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","volume":"379","author":"T Palmerini","year":"2012","unstructured":"Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393\u2013402. A large contemporary meta-analysis of drug-eluting stents versus bare-metal stents, demonstrating superior efficacy with DES, and for the first time significant reductions in stent thrombosis with those treated with everolimus-eluting stents compared with bare-metal stents.","journal-title":"Lancet"},{"issue":"13","key":"219_CR30","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","volume":"123","author":"K Kolandaivelu","year":"2011","unstructured":"Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123(13):1400\u20139.","journal-title":"Circulation."},{"issue":"23","key":"219_CR31","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","volume":"125","author":"S Bangalore","year":"2012","unstructured":"Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125(23):2873\u201391.","journal-title":"Circulation."},{"issue":"3","key":"219_CR32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCINTERVENTIONS.111.967083","volume":"5","author":"T Palmerini","year":"2012","unstructured":"Palmerini T, Kirtane AJ, Serruys PW, et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv. 2012;5(3):357\u201364.","journal-title":"Circ Cardiovasc Interv."},{"issue":"11","key":"219_CR33","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jacc.2011.01.011","volume":"57","author":"G Nakazawa","year":"2011","unstructured":"Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57(11):1314\u201322.","journal-title":"J Am Coll Cardiol."},{"issue":"9644","key":"219_CR34","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(08)61244-1","volume":"372","author":"S Windecker","year":"2008","unstructured":"Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372(9644):1163\u201373.","journal-title":"Lancet."},{"issue":"9807","key":"219_CR35","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(11)61672-3","volume":"378","author":"GG Stefanini","year":"2011","unstructured":"Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011;378(9807):1940\u20138. An important paper reporting the four-year outcomes from the LEADERS study, and which demonstrates a significant reduction in very late stent thrombosis with the biolimus-eluting stent with a biodegradable polymer, compared with the permanent polymer sirolimus-eluting stent.","journal-title":"Lancet"},{"issue":"10","key":"219_CR36","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","volume":"33","author":"GG Stefanini","year":"2012","unstructured":"Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33(10):1214\u201322.","journal-title":"Eur Heart J."},{"issue":"2","key":"219_CR37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/eurheartj\/ehp480","volume":"31","author":"P Barlis","year":"2010","unstructured":"Barlis P, Regar E, Serruys PW, et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J. 2010;31(2):165\u201376.","journal-title":"Eur Heart J."},{"issue":"5","key":"219_CR38","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ahj.2011.09.005","volume":"162","author":"JL Gutierrez-Chico","year":"2011","unstructured":"Gutierrez-Chico JL, Juni P, Garcia-Garcia HM, et al. Long-term tissue coverage of a biodegradable polylactide polymer-coated biolimus-eluting stent: comparative sequential assessment with optical coherence tomography until complete resorption of the polymer. Am Heart J. 2011;162(5):922\u201331.","journal-title":"Am Heart J."},{"issue":"15","key":"219_CR39","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2011.12.016","volume":"59","author":"IT Meredith","year":"2012","unstructured":"Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol. 2012;59(15):1362\u201370.","journal-title":"J Am Coll Cardiol."},{"issue":"10 Suppl","key":"219_CR40","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2010.06.008","volume":"56","author":"S Garg","year":"2010","unstructured":"Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol. 2010;56(10 Suppl):S43\u201378. An in-depth review paper that summarises the development and assessment of new coronary stents..","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"219_CR41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCINTERVENTIONS.109.877522","volume":"3","author":"N Tada","year":"2010","unstructured":"Tada N, Virmani R, Grant G, et al. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv. 2010;3(2):174\u201383.","journal-title":"Circ Cardiovasc Interv."},{"issue":"5","key":"219_CR42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.111.026732","volume":"124","author":"S Massberg","year":"2011","unstructured":"Massberg S, Byrne RA, Kastrati A, et al. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the intracoronary stenting and angiographic results: test efficacy of sirolimus- and probucol-eluting versus zotarolimus-eluting stents (ISAR-TEST 5) Trial. Circulation. 2011;124(5):624\u201332.","journal-title":"Circulation."},{"issue":"22","key":"219_CR43","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1161\/CIRCULATIONAHA.109.921528","volume":"122","author":"Y Onuma","year":"2010","unstructured":"Onuma Y, Serruys PW, Perkins LE, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010;122(22):2288\u2013300. An important paper that summarises the pre-clinical data of the bioresobable vascular scaffold.","journal-title":"Circulation"},{"issue":"9616","key":"219_CR44","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0140-6736(08)60415-8","volume":"371","author":"JA Ormiston","year":"2008","unstructured":"Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371(9616):899\u2013907.","journal-title":"Lancet."},{"issue":"9667","key":"219_CR45","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0140-6736(09)60325-1","volume":"373","author":"PW Serruys","year":"2009","unstructured":"Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667):897\u2013910.","journal-title":"Lancet."},{"issue":"22","key":"219_CR46","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1161\/CIRCULATIONAHA.110.970772","volume":"122","author":"PW Serruys","year":"2010","unstructured":"Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122(22):2301\u201312.","journal-title":"Circulation."},{"issue":"15","key":"219_CR47","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.jacc.2011.05.050","volume":"58","author":"PW Serruys","year":"2011","unstructured":"Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58(15):1578\u201388.","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"219_CR48","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/eurheartj\/ehr466","volume":"33","author":"S Brugaletta","year":"2012","unstructured":"Brugaletta S, Heo JH, Garcia-Garcia HM, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J. 2012;33(11):1325\u201333.","journal-title":"Eur Heart J."},{"issue":"9","key":"219_CR49","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.4244\/EIJV7I9A168","volume":"7","author":"D Dudek","year":"2012","unstructured":"Dudek D, Onuma Y, Ormiston JA, et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2012;7(9):1060\u20131.","journal-title":"EuroIntervention."},{"key":"219_CR50","volume-title":"Long-term (>10\u00a0years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents","author":"S Nishio","year":"2010","unstructured":"Nishio S, Kosuga K, Okada M, et al. Long-term (>10\u00a0years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents. Paris: Presentation at EuroPCR; 2010."},{"key":"219_CR51","doi-asserted-by":"crossref","unstructured":"Camenzind E, Wijns W, Mauri L et al. Stent thrombosis and major clinical events at 3\u00a0years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. The Lancet. 2012. An landmark paper on the safety of coronary stents, and the first study to report stent thrombosis as its primary endpoint.","DOI":"10.1016\/S0140-6736(12)61336-1"},{"issue":"17","key":"219_CR52","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","volume":"293","author":"I Iakovou","year":"2005","unstructured":"Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126\u201330.","journal-title":"JAMA."},{"issue":"7","key":"219_CR53","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/CIRCULATIONAHA.106.686048","volume":"116","author":"F Airoldi","year":"2007","unstructured":"Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116(7):745\u201354.","journal-title":"Circulation."},{"issue":"15","key":"219_CR54","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","volume":"362","author":"SJ Park","year":"2010","unstructured":"Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362(15):1374\u201382.","journal-title":"N Engl J Med."},{"issue":"16","key":"219_CR55","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","volume":"125","author":"M Valgimigli","year":"2012","unstructured":"Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125(16):2015\u201326.","journal-title":"Circulation."},{"key":"219_CR56","doi-asserted-by":"crossref","unstructured":"Byrne RA, Schulz S, Mehilli J, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J. 2009;157(4):620\u20134.e2.","DOI":"10.1016\/j.ahj.2008.12.019"},{"issue":"6","key":"219_CR57","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ahj.2010.07.038","volume":"160","author":"L Mauri","year":"2010","unstructured":"Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010;160(6):1035\u201341, 41 e1.","journal-title":"Am Heart J"},{"key":"219_CR58","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","volume":"31","author":"W Wijns","year":"2010","unstructured":"Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31:2501\u201355. The European revascularization guidelines\u2014a vital read.","journal-title":"Eur Heart J"},{"key":"219_CR59","unstructured":"Dewilde W. WOEST: What is the Optimal Antiplatelet and Anticoagulant Therapy in Patients with Oral Anticoagulation and Coronary Stenting. Presented at the European Society of Cardiology Congress 28 August 2012, Munich, Germany. 2012."},{"issue":"24","key":"219_CR60","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","volume":"58","author":"GN Levine","year":"2011","unstructured":"Levine GN, Bates ER, Blankenship JC, et al. ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44\u2013122. The American revascularization guidelines\u2014a vital read.","journal-title":"J Am Coll Cardiol."},{"issue":"18","key":"219_CR61","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1001\/jama.297.18.2001","volume":"297","author":"HK Win","year":"2007","unstructured":"Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297(18):2001\u20139.","journal-title":"JAMA."},{"issue":"4","key":"219_CR62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcin.2008.06.005","volume":"1","author":"BR Brodie","year":"2008","unstructured":"Brodie BR, Stuckey T, Downey W, et al. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group. JACC Cardiovasc Interv. 2008;1(4):405\u201314.","journal-title":"JACC Cardiovasc Interv."},{"issue":"2","key":"219_CR63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1004130","volume":"363","author":"PW Serruys","year":"2010","unstructured":"Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136\u201346.","journal-title":"N Engl J Med."},{"issue":"17","key":"219_CR64","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1093\/eurheartj\/ehr126","volume":"32","author":"SP Boer de","year":"2011","unstructured":"de Boer SP, Lenzen MJ, Oemrawsingh RM, et al. Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants. Eur Heart J. 2011;32(17):2161\u20137.","journal-title":"Eur Heart J."},{"key":"219_CR65","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2009.11.049","volume":"55","author":"PW Serruys","year":"2010","unstructured":"Serruys PW, Onuma Y, Garg S, et al. 5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol. 2010;55:1093\u2013101.","journal-title":"J Am Coll Cardiol."},{"issue":"10","key":"219_CR66","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa0804626","volume":"360","author":"PW Serruys","year":"2009","unstructured":"Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961\u201372.","journal-title":"N Engl J Med."},{"issue":"5","key":"219_CR67","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacc.2009.10.014","volume":"55","author":"A Kapur","year":"2010","unstructured":"Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010;55(5):432\u201340.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"219_CR68","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2012.03.016","volume":"5","author":"PW Serruys","year":"2012","unstructured":"Serruys PW, Farooq V, Vranckx P, et al. A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years. JACC Cardiovasc Interv. 2012;5(6):606\u201317.","journal-title":"JACC Cardiovasc Interv."},{"key":"219_CR69","unstructured":"Serruys PW. The 4-year outcomes of the SYNTAX trial. Presentation at European Association of Cardiothoracic Surgeons annual meeting, Lisbon, Portugal on October 2011."},{"key":"219_CR70","unstructured":"Shiomi H. Comparison of three-year outcome after PCI and CABG stratified by the SYNTAX score in patients with triple vessel coronary artery disease: an observation from the CREDO-Kyoto PCI\/CABG registry Cohort-2. Presentation at European Society of Cardiology meeting, Paris, Aug 29th 2011."},{"issue":"16","key":"219_CR71","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa1110717","volume":"366","author":"WS Weintraub","year":"2012","unstructured":"Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med. 2012;366(16):1467\u201376.","journal-title":"N Engl J Med."},{"issue":"18","key":"219_CR72","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1100452","volume":"364","author":"SJ Park","year":"2011","unstructured":"Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med. 2011;364(18):1718\u201327.","journal-title":"N Engl J Med."},{"issue":"5","key":"219_CR73","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jacc.2010.09.038","volume":"57","author":"E Boudriot","year":"2011","unstructured":"Boudriot E, Thiele H, Walther T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol. 2011;57(5):538\u201345.","journal-title":"J Am Coll Cardiol."},{"issue":"5","key":"219_CR74","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jacc.2007.09.054","volume":"51","author":"PE Buszman","year":"2008","unstructured":"Buszman PE, Kiesz SR, Bochenek A, et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol. 2008;51(5):538\u201345.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"219_CR75","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4244\/EIJV7I6A117","volume":"7","author":"G Ferrante","year":"2011","unstructured":"Ferrante G, Presbitero P, Valgimigli M, et al. Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials. EuroIntervention. 2011;7(6):738\u201346. A meta-analysis of randomised studies comparing drug-eluting stents with coronary artery bypass surgery.","journal-title":"EuroIntervention"},{"key":"219_CR76","doi-asserted-by":"crossref","unstructured":"Jang JS, Choi KN, Jin HY et al. meta-analysis of three randomized trials and nine observational studies comparing drug-eluting stents versus coronary artery bypass grafting for unprotected left main coronary artery disease. Am J Cardiol. 2012.","DOI":"10.1016\/j.amjcard.2012.06.051"},{"issue":"3","key":"219_CR77","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0735-1097(98)00286-1","volume":"32","author":"A Abizaid","year":"1998","unstructured":"Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998;32(3):584\u20139.","journal-title":"J Am Coll Cardiol."},{"key":"219_CR78","doi-asserted-by":"crossref","first-page":"e5170","DOI":"10.1136\/bmj.e5170","volume":"345","author":"S Bangalore","year":"2012","unstructured":"Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials. BMJ. 2012;345:e5170.","journal-title":"BMJ."},{"key":"219_CR79","doi-asserted-by":"crossref","first-page":"a1331","DOI":"10.1136\/bmj.a1331","volume":"337","author":"C Stettler","year":"2008","unstructured":"Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008;337:a1331.","journal-title":"BMJ."},{"issue":"8","key":"219_CR80","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/CIRCULATIONAHA.110.015453","volume":"124","author":"WJ Kim","year":"2011","unstructured":"Kim WJ, Lee SW, Park SW, et al. Randomized Comparison of Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients With Diabetes Mellitus (ESSENCE-DIABETES): Results From the ESSENCE-DIABETES Trial. Circulation. 2011;124(8):886\u201392.","journal-title":"Circulation."},{"issue":"9","key":"219_CR81","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.amjcard.2011.06.037","volume":"108","author":"M Maeng","year":"2011","unstructured":"Maeng M, Jensen LO, Tilsted HH, et al. Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). Am J Cardiol. 2011;108(9):1232\u20137.","journal-title":"Am J Cardiol."},{"key":"219_CR82","doi-asserted-by":"crossref","unstructured":"Kapur A, Baumbach A, Beatt K et al. CARDia: Coronary Artery Revascularisation in Diabetes Trial. Presentation at the European Society of Cardiology congress, Munich, Germany, August 27th 2012. 2012.","DOI":"10.1186\/ISRCTN19872154"},{"key":"219_CR83","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jacc.2009.09.057","volume":"55","author":"A Banning","year":"2010","unstructured":"Banning A, Westaby S, Morice MC, et al. Comparison of cardiac surgery and paclitaxel-eluting stents in nondiabetic and diabetic patients with left main and\/or 3-vessel coronary artery disease. J Am Coll Cardiol. 2010;55:1067\u201375.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"219_CR84","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.athoracsur.2011.06.028","volume":"92","author":"MJ Mack","year":"2011","unstructured":"Mack MJ, Banning AP, Serruys PW, et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg. 2011;92(6):2140\u20136.","journal-title":"Ann Thorac Surg"},{"issue":"19","key":"219_CR85","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.jacc.2011.02.011","volume":"57","author":"RS Wright","year":"2011","unstructured":"Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF\/AHA focused update incorporated into the ACC\/AHA 2007 Guidelines for the Management of Patients with Unstable Angina\/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):e215\u2013367.","journal-title":"J Am Coll Cardiol."},{"key":"219_CR86","unstructured":"Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012."},{"issue":"19","key":"219_CR87","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa0810116","volume":"360","author":"GW Stone","year":"2009","unstructured":"Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009;360(19):1946\u201359.","journal-title":"N Engl J Med."},{"issue":"18","key":"219_CR88","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jacc.2009.03.013","volume":"53","author":"SS Brar","year":"2009","unstructured":"Brar SS, Leon MB, Stone GW, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol. 2009;53(18):1677\u201389.","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"219_CR89","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/archinternmed.2012.758","volume":"172","author":"G Luca De","year":"2012","unstructured":"De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012;172(8):611\u201321; discussion 21\u20132.","journal-title":"Arch Intern Med"},{"issue":"8","key":"219_CR90","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/eurheartj\/ehs036","volume":"33","author":"B Kalesan","year":"2012","unstructured":"Kalesan B, Pilgrim T, Heinimann K, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(8):977\u201387.","journal-title":"Eur Heart J."},{"key":"219_CR91","unstructured":"Sabate M, Cequier A, Iniguez A et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. 2012. The first all-comers STEMI study that used a second-generation DES."},{"issue":"8","key":"219_CR92","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/jama.2012.10065","volume":"308","author":"L R\u00e4ber","year":"2012","unstructured":"R\u00e4ber L, Kelb\u00e6k H, Ostoijc M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA. 2012;308(8):777\u201387.","journal-title":"JAMA."},{"issue":"5","key":"219_CR93","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jacc.2012.01.073","volume":"60","author":"SH Hofma","year":"2012","unstructured":"Hofma SH, Brouwer J, Velders MA, et al. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) Trial. J Am Coll Cardiol. 2012;60(5):381\u20137.","journal-title":"J Am Coll Cardiol."},{"issue":"21","key":"219_CR94","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","volume":"122","author":"PG Steg","year":"2010","unstructured":"Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122(21):2131\u201341.","journal-title":"Circulation."},{"issue":"9665","key":"219_CR95","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","volume":"373","author":"G Montalescot","year":"2009","unstructured":"Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723\u201331.","journal-title":"Lancet."}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-012-0219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-012-0219-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-012-0219-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T02:17:53Z","timestamp":1562379473000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-012-0219-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,29]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1007\/s11936-012-0219-0","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,29]]}}}